Exploration of the Synovial Fluid Inflammation Mediators Under Diacerhein in Knee Osteoarthritis
Phase 4
Completed
- Conditions
- Osteoarthritis
- Registration Number
- NCT00440661
- Lead Sponsor
- Laboratoires NEGMA
- Brief Summary
Some inflammation mediators, notably IL-1, are implied in the joint degeneration phenomena of osteoarthritis. The aim of this study is to confirm in vivo the favourable effect of diacerhein on IL-1 and also to appreciate its effect on other synovial inflammation mediators.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 96
Inclusion Criteria
- Painful osteoarthritis
- Hydarthrosis (synovial effusion)
Exclusion Criteria
- large effusion
- severe pathologies
- anti-osteoarthritic treatments
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Synovial concentration of IL-1
- Secondary Outcome Measures
Name Time Method WOMAC Synovial concentration of IL-6
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the mechanism of Diacerhein's anti-inflammatory effect on IL-1 in knee osteoarthritis synovial fluid?
How does Diacerhein compare to NSAIDs in modulating synovial inflammation markers in knee OA patients?
Are there specific biomarkers in synovial fluid that predict Diacerhein response in osteoarthritis?
What are the long-term safety profiles of Diacerhein in Phase IV knee osteoarthritis trials?
What other disease-modifying osteoarthritis drugs (DMOADs) show similar synovial mediator effects as Diacerhein?
Trial Locations
- Locations (1)
Rheumatologic Institut of Montreal
🇨🇦Montreal, Quebec, Canada
Rheumatologic Institut of Montreal🇨🇦Montreal, Quebec, Canada